Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-004335
Filing Date
2017-05-15
Accepted
2017-05-15 16:09:46
Documents
56
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20170331x10q.htm 10-Q 1648684
2 EX-31.1 syrs-20170331ex311724150.htm EX-31.1 10094
3 EX-31.2 syrs-20170331ex3125cc4bb.htm EX-31.2 10637
4 EX-32.1 syrs-20170331ex321fb65b7.htm EX-32.1 7279
5 EX-32.2 syrs-20170331ex322d36a8f.htm EX-32.2 7294
  Complete submission text file 0001558370-17-004335.txt   5344007

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20170331.xml EX-101.INS 1015358
7 EX-101.SCH syrs-20170331.xsd EX-101.SCH 33280
8 EX-101.CAL syrs-20170331_cal.xml EX-101.CAL 37905
9 EX-101.DEF syrs-20170331_def.xml EX-101.DEF 146379
10 EX-101.LAB syrs-20170331_lab.xml EX-101.LAB 367774
11 EX-101.PRE syrs-20170331_pre.xml EX-101.PRE 266115
Mailing Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 17844275
SIC: 2834 Pharmaceutical Preparations